Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
Open Access
- 24 January 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 22 (4), 756-761
- https://doi.org/10.1038/sj.leu.2405097
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNature Reviews Cancer, 2007
- The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraBlood, 2007
- Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burdenLeukemia, 2007
- A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemiaLeukemia, 2007
- TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutationsLeukemia, 2007
- JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorderLeukemia, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic featuresLeukemia, 2006
- MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid MetaplasiaPLoS Medicine, 2006
- JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplainedLeukemia, 2006